Overview

A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies

Status:
Unknown status

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

To determine the rate of response and duration of reponse following therapy with Aroplatin in subjects with advanced colorectal cancer resistant to standard therapies. Secondary objectives are to determine safety and tolerability of the Aroplatin therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Aronex Pharmaceuticals

Treatments:

bis-neodecanoato-1,2-diaminocyclohexaneplatinum(II)